|
448 Products |
| 448 Products |
|
1070 Diseases |  |
113911 News |  |
| «12...5455565758596061626364...11171118» |
- || Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Review, Journal: Botulinum Toxin A as an Adjunct for the Repair Giant Inguinal Hernias: Case Reports and a Review of the Literature. (Pubmed Central) - Apr 13, 2024
While the literature on this topic is scarce, we found 13 cases of inguinal hernias treated with BTA as an adjunct. BTA might be a promising adjunct for the management of giant inguinoscrotal hernias in addition to or in place of current strategies.
- | Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
Journal: Cariprazine as a maintenance therapy in the prevention of mood episodes in adults with bipolar I disorder. (Pubmed Central) - Apr 13, 2024
Relapse rates were unusually low in the placebo group. Cariprazine was well-tolerated.
- || escitalopram / Generic mfg.
Clinical, Journal: Efficacy of whole system ayurveda management protocol in major depressive disorder- A randomized controlled clinical trial. (Pubmed Central) - Apr 13, 2024
WSAP was effective in management of MDD and had better side effect profile. Further studies needed.
- | mirtazapine / Generic mfg.
Journal: Treatment of Progressive Multifocal Leukoencephalopathy with IL-2 and Mirtazapine. (Pubmed Central) - Apr 12, 2024
Further studies needed. No abstract available
- | Journal: Antipsychotic prescribing: national findings of children and adolescents attending mental health services in Ireland. (Pubmed Central) - Apr 12, 2024
This is the first study in children and adolescents that describes the target conditions and target symptoms for antipsychotic use in Ireland. Our results show a high proportion of antipsychotic prescribing based on target symptoms rather than target condition or diagnosis.
- | amitriptyline / Generic mfg., propranolol / Generic mfg.
Journal, Monotherapy: Comparison of the efficacy of propranolol versus amitriptyline as monotherapy for prophylaxis of migraine. (Pubmed Central) - Apr 12, 2024
When administered for migraine prevention, it generates a quick response within 3 months. Propranolol is less effective than amitriptyline at reducing the frequency, length, and severity of episodes.
- || clozapine / Generic mfg.
Review, Journal: Exploring clozapine use in severe psychiatric symptoms associated with autism spectrum disorder: A scoping review. (Pubmed Central) - Apr 12, 2024
While clozapine shows promise as a pharmacological intervention for severe psychopathologies in ASD, more rigorous clinical studies are required to elucidate its efficacy and safety in this population. The limited robustness of the evidence calls for caution, signaling an early research stage into this topic.
- | clozapine / Generic mfg.
Journal: The prevalence of constipation in adult psychiatric out-patients on clozapine treatment at a regional public hospital in Hong Kong. (Pubmed Central) - Apr 12, 2024
This study examined the prevalence of clozapine-associated constipation in Hong Kong using a validated questionnaire. The identification of independent factors associated with constipation could facilitate better risk stratification and risk modification in clinical practice.
- | Clopixol (zuclopenthixol) / Lundbeck
Biomarker, Observational data, Journal: Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study. (Pubmed Central) - Apr 12, 2024
There were no statistically significant differences between age, sex, or ethnicity in the likelihood of being prescribed a 'CYP2D6-PGx antipsychotic'. This study demonstrated high rates of prescribing 'CYP2D6-PGx-antipsychotics' in an EIP cohort, providing a rationale for further exploration of how PGx testing can be implemented in EIP services to personalise the prescribing of drugs for psychosis.
- | Trintellix (vortioxetine) / Lundbeck, Takeda
Journal: Impact of Baseline Anxiety on Well-Being in Persons with Post-COVID-19 Condition: A Secondary Analysis. (Pubmed Central) - Apr 12, 2024
P2
We also identified a robust correlation between anxiety in PCC and measures of general well-being. Our results require replication, providing the impetus for recommending screening and targeting anxious symptoms as a tactic to improve general well-being and outcomes in individuals with PCC.
- | midomafetamine (MDMA) / Multidisciplinary Association for Psychedelic Studies (MAPS)
Trial initiation date: MDMA-assisted Therapy for Fibromyalgia (clinicaltrials.gov) - Apr 12, 2024
P1, N=20, Not yet recruiting, Sponsor: Spaulding Rehabilitation Hospital
Our results require replication, providing the impetus for recommending screening and targeting anxious symptoms as a tactic to improve general well-being and outcomes in individuals with PCC. Initiation date: Mar 2024 --> Aug 2024
- | omeprazole / Generic mfg., etoricoxib / Generic mfg., duloxetine / Generic mfg.
Biomarker, Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Biomarkers for Prediction of Analgesic Efficacy in Knee OA. (clinicaltrials.gov) - Apr 12, 2024
P=N/A, N=17, Completed, Sponsor: Rambam Health Care Campus
Initiation date: Mar 2024 --> Aug 2024 Recruiting --> Completed | N=100 --> 17 | Trial completion date: Dec 2023 --> Apr 2024 | Trial primary completion date: Aug 2023 --> Apr 2024
- New Development of Antipsychotic Drugs in Schizophrenia (Virtual Session | Online| Zoom Meeting) - Apr 12, 2024 - Abstract #NDS2024NDS_83;
Among these newer antipsychotic drugs are cariprazine, brexipiprazole and lumateperone, which exert a partial agonistic effect at D2 and 5-HT2A receptors, pimvanserin a 5-HT2A receptor antagonist which treats negative schizophrenic symptoms as an add-on therapy, olanzapine combined with samidorphan, which reduces weight gain, and M4 or M1 receptor agonists, for example xanomeline with an antipsychotic effect combined with tropsium, an anticholinergic drug...Pimavanserin reduces negative schizophrenic symptoms as an additional pharmacotherapy in schizophrenia...The long-term efficacy should still be examined. Newer antipsychotic drugs are for example xanomeline, a M4 or M1 receptor agonist, which has been combined with tropsium, an anticholinergic drug, the mechanism of action of which can be derived from the neural network suggested in this review.
- clozapine / Generic mfg.
Interrogation of the Chlorine Atom in the Atypical Antipsychotic Clozapine and Insilico Investigation of Other Potential Pharmacophores in This Context (In-Person; MARBELLA) - Apr 12, 2024 - Abstract #NDS2024NDS_37;
The results show that the newly designed clozapine derivatives are superior to clozapine. The designed molecular structures will also be tested by further experimental studies to verify the obtained results.
- | olanzapine / Generic mfg., haloperidol / Generic mfg.
Trial completion date, Trial primary completion date: HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial (clinicaltrials.gov) - Apr 11, 2024
P3, N=72, Recruiting, Sponsor: Tan Tock Seng Hospital
The designed molecular structures will also be tested by further experimental studies to verify the obtained results. Trial completion date: Apr 2023 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2024
- | Resolor (prucalopride) / J&J, Takeda
Trial completion date, Trial primary completion date: The Effect of Prucalopride on Gastric Emptying in Intensive Care Unit Patients (clinicaltrials.gov) - Apr 11, 2024
P1/2, N=70, Completed, Sponsor: Ain Shams University
Trial completion date: Apr 2023 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2024 Trial primary completion date: Jul 2022 --> Jun 2023 | Trial completion date: Jul 2022 --> Jul 2023
- | clozapine / Generic mfg.
Journal: Glycine and clozapine: potential relevance for the treatment of Parkinson's disease. (Pubmed Central) - Apr 11, 2024
Trial primary completion date: Jul 2022 --> Jun 2023 | Trial completion date: Jul 2022 --> Jul 2023 No abstract available
- || Savella (milnacipran) / AbbVie, Pierre Fabre
Review, Journal: Pharmacological Treatments for Localized Provoked Vulvodynia: A Scoping Review. (Pubmed Central) - Apr 11, 2024
Oral gabapentin and oral desipramine showed some improvement in sexual function compared to placebo...Pain was reduced in descriptive studies of tricyclic antidepressants, milnacipran, injectable anesthetics, and botulinum toxin...The breadth of therapies for treating LPV warrants the development of evidence-based, consensus guidelines for measuring treatment outcomes and improving comparisons across studies. Recommendations for research include addressing methodological shortcomings and diversifying the participant pool to increase the generalizability of findings.
- | clozapine / Generic mfg.
Journal: Clinical and pharmacological factors influencing serum clozapine and norclozapine levels. (Pubmed Central) - Apr 11, 2024
The use of CLO at recommended doses does not guarantee achieving therapeutic concentrations of CLO or NCLO. Women and nonsmokers were at the highest risk of having toxic CLO levels.
- | Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Journal: Treatment of Frey Syndrome with Botulinum Toxin-A: A Practical Approach from Minor's Test to Injection. (Pubmed Central) - Apr 11, 2024
Additionally, the gold standard of treatment for established Frey's syndrome, botulinum toxin A, is thoroughly described, including its mechanism of action, administration, and potential side effects. Finally, the article underscores the need for further research to enhance our understanding of Frey's syndrome, leading to better diagnostic methods and more tailored treatment options for patients.
- || duloxetine / Generic mfg.
Review, Journal: Current and future advances in practice: aromatase inhibitor-induced arthralgia. (Pubmed Central) - Apr 11, 2024
There was consistent improvement in AIAs with switching to an alternate AI, and this could additionally allow continuation of cancer treatment with AI. Further research is needed to identify predictive biomarkers, better characterize AIA subcategories and study more reliable therapeutic options.
- || aripiprazole / Generic mfg.
Retrospective data, Review, Journal: Examining the Use of Oral Aripiprazole in Patients With Autism Spectrum Disorder: A Study of Retrospective Chart Review at a University Medical Center. (Pubmed Central) - Apr 11, 2024
The most commonly reported adverse effects were increased appetite and weight gain, which in some cases led to discontinuation of medication. A follow-up study is warranted to evaluate the efficacy and safety of aripiprazole treatment in Korean children and adolescents diagnosed with ASD, and it is crucial to consider their clinical characteristics and response to treatment in the evaluation.
- ||| botulinum toxin type A (ABBV-950) / AbbVie
Enrollment closed, Adverse events: Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity (clinicaltrials.gov) - Apr 11, 2024
P1/2, N=297, Active, not recruiting, Sponsor: AbbVie
A follow-up study is warranted to evaluate the efficacy and safety of aripiprazole treatment in Korean children and adolescents diagnosed with ASD, and it is crucial to consider their clinical characteristics and response to treatment in the evaluation. Recruiting --> Active, not recruiting
- | Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Journal: Is bulbospongiosus muscle botox injection safe and effective in treating lifelong premature ejaculation? Randomized controlled study. (Pubmed Central) - Apr 10, 2024
Our study demonstrated that the injection of botulinum-A toxin into the bulbospongiosus muscle can serve as a safe and effective option for treating PE. Nonetheless, its clinical application warrants further studies involving larger sample sizes and longer follow-up periods.
- | amitriptyline / Generic mfg., carbamazepine / Generic mfg.
Journal: Clinical Effects of Combined Use of Carbamazepine and Amitriptyline in the Treatment of Diabetic Neuropathy with Concurrent Diabetic Foot. (Pubmed Central) - Apr 10, 2024
It effectively alleviates symptoms, improves psychological well-being, reduces pain sensation, and enhances overall quality of life. These findings can guide physicians in adopting a more evidence-based treatment approach and provide patients with more effective individualized treatment strategies.
- || eszopiclone / Generic mfg., trazodone ER / Generic mfg.
Retrospective data, Review, Journal: Pharmacological interventions to improve sleep in people with Alzheimer's disease: a meta-analysis of randomized controlled trials. (Pubmed Central) - Apr 10, 2024
Although melatonin was the most investigated intervention, the evidence for its efficacy is inconclusive. On the other hand, trazodone and orexin receptor antagonists showed promising results; however, more RCTs are needed for definite answers.
- | Trintellix (vortioxetine) / Lundbeck, Takeda
Journal: An anti-depressant drug vortioxetine suppresses malignant glioblastoma cell growth. (Pubmed Central) - Apr 10, 2024
We also showed that vortioxetine inhibited the migration of glioblastoma cells as compared to the control. Our findings encourage further exploration and validation of the use of vortioxetine in the treatment of glioblastoma.
- | venlafaxine / Generic mfg., pregabalin / Generic mfg., amitriptyline / Generic mfg.
Journal: Persistent facial pain in post-stroke patients, a hospital-based cohort study; experience from North India. (Pubmed Central) - Apr 10, 2024
It responds adequately to antidepressants. A high index of suspicion is required to diagnose and appropriately manage these patients.
- | venlafaxine / Generic mfg., fluoxetine / Generic mfg.
Journal: Association of the Antidepressants and the Periodontal Status: An Original Research. (Pubmed Central) - Apr 10, 2024
Number, percentage, mean, and standard deviation were used to present the values. Results showed that antidepressants may be a risk factor for periodontal health, with increased periodontal parameters, and concluded that It is crucial to frequently check the periodontal health of depressed people using fluoxetine or venlafaxine since these drugs put good periodontal tissues at risk.
- | ulotaront (SEP-363856) / Sumitomo Pharma, Otsuka, PsychoGenics
Journal: Discovery of potential TAAR1 agonist targeting neurological and psychiatric disorders: An in silico approach. (Pubmed Central) - Apr 10, 2024
The lead compound showed promising binding affinity and stable interactions with TAAR1 during molecular dynamics simulations and demonstrated better van der Waals and binding energy than the known agonist, ulotaront. Our findings suggest that the lead compound may serve as a potential TAAR1 agonist, offering a promising avenue for the development of new therapies for neurological and psychiatric disorders.
- | Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Trial primary completion date: Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders (clinicaltrials.gov) - Apr 10, 2024
P2, N=75, Recruiting, Sponsor: Tanta University
Our findings suggest that the lead compound may serve as a potential TAAR1 agonist, offering a promising avenue for the development of new therapies for neurological and psychiatric disorders. Trial primary completion date: Mar 2024 --> Nov 2024
- | Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment change, Trial withdrawal: Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache (clinicaltrials.gov) - Apr 10, 2024
P1, N=0, Withdrawn, Sponsor: University of Alberta
Trial primary completion date: Mar 2024 --> Nov 2024 N=80 --> 0 | Not yet recruiting --> Withdrawn
- | Lybalvi (olanzapine/samidorphan) / Alkermes
Journal, Real-world evidence, Real-world: Treating Schizophrenia and Bipolar I Disorder in the Real-World Setting: Effectiveness and Safety of Olanzapine/Samidorphan Combination. (Pubmed Central) - Apr 9, 2024
N=80 --> 0 | Not yet recruiting --> Withdrawn No abstract available
- | risperidone / Generic mfg.
Journal: Hepatotoxicity to Risperidone. (Pubmed Central) - Apr 9, 2024
No abstract available No abstract available
- | olanzapine / Generic mfg.
Journal: A case report of a patient with Turner syndrome who develops catatonia secondary to psychotic symptoms. (Pubmed Central) - Apr 9, 2024
No abstract available For patients with TS who present with psychotic symptoms and catatonia, a comprehensive evaluation is necessary, and treatment with antipsychotics and benzodiazepines is effective.
- | aripiprazole / Generic mfg., haloperidol / Generic mfg., clozapine / Generic mfg.
Journal: Antipsychotic drugs selectively decorrelate long-range interactions in deep cortical layers. (Pubmed Central) - Apr 9, 2024
We found that clozapine as well as two other antipsychotic drugs, aripiprazole and haloperidol, resulted in a strong reduction in correlations of layer 5 activity between cortical areas and impaired the spread of visuomotor prediction errors generated in visual cortex. Our results are consistent with the interpretation that a major functional effect of antipsychotic drugs is a selective alteration of long-range layer 5-mediated communication.
- | lithium carbonate ER / Generic mfg.
Journal: Drugs for bipolar disorder. (Pubmed Central) - Apr 9, 2024
Our results are consistent with the interpretation that a major functional effect of antipsychotic drugs is a selective alteration of long-range layer 5-mediated communication. No abstract available
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Persistence, health care resource utilization, and costs among onabotulinumtoxinA-treated patients with cervical dystonia in the United States () - Apr 9, 2024 - Abstract #AMCP2024AMCP_343;
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Real-world-outcomes of CGRP agents and onabotulinumtoxinA as combination therapy for the treatment of migraine in adults () - Apr 9, 2024 - Abstract #AMCP2024AMCP_249;
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Health care resource utilization associated with use of calcitonin gene-related peptide (CGRP) antagonists and onabotulinumtoxinA (Botox) for migraine prophylaxis () - Apr 9, 2024 - Abstract #AMCP2024AMCP_246;
- Spravato (esketamine intranasal) / J&J
Comparing efficacy and safety of Symbyax (olanzapine-fluoxetine), Seroquel XR (quetiapine XR), and Spravato (intranasal esketamine) for treatment-resistant depression: A literature review () - Apr 9, 2024 - Abstract #AMCP2024AMCP_237;
- Linzess (linaclotide) / Astellas, Ironwood Pharma, AbbVie, Trulance (plecanatide) / Bausch Health, Resolor (prucalopride) / J&J, Takeda
Treatment patterns, barriers, and associated costs reported by patients with chronic idiopathic constipation in the United States: Analysis from a cross-sectional observational study () - Apr 9, 2024 - Abstract #AMCP2024AMCP_140;
The high- est out-of-pocket costs for patients were related to seeing an HCP and those associated with OTC and prescription medications. These factors may affect patient access to therapies for CIC.
- Rexulti (brexpiprazole) / Lundbeck, Otsuka
Early adjunctive brexpiprazole initiation for major depressive disorder: Impact on health care resource utilization and cost () - Apr 9, 2024 - Abstract #AMCP2024AMCP_100;
In this analysis of more than 1,000 adults, late initiation of brexpiprazole beyond 1 year after first ADT was associated with significantly higher outpatient health care utilization and cost in real-world practice. Early in- tervention with adjunct brexpiprazole may reduce HCRU burden and cost among adults with MDD.
- Lybalvi (olanzapine/samidorphan) / Alkermes
Health care resource utilization following 6 months of treatment with olanzapine/ samidorphan: Real-world assessment of patients with schizophrenia or bipolar I disorder () - Apr 9, 2024 - Abstract #AMCP2024AMCP_99;
This is the first real-world study to assess HCRU 6 months before and after OLZ/SAM initiation. Among patients with SZ or BD-I, OLZ/SAM initiation was associated with significant reductions in the proportions of patients with all-cause and mental health
- aripiprazole / Generic mfg., risperidone / Generic mfg.
Baseline demographics and clinical characteristics from OASIS: Observational Study of Long-Acting Injectables in Schizophrenia () - Apr 9, 2024 - Abstract #AMCP2024AMCP_98;
P=N/A
Despite symptoms present, only approximately one-third of patients used an antipsy- chotic in the 12 months before aLAI initiation. These findings from a real-world study increase our understanding of the role of aLAI antipsychotics in schizophrenia.
- aripiprazole / Generic mfg., risperidone / Generic mfg.
Treatment patterns and outcomes from OASIS: Observational Study of Long-Acting Injectables in Schizophrenia () - Apr 9, 2024 - Abstract #AMCP2024AMCP_97;
P=N/A
These findings from a real-world study increase our understanding of the role of aLAI antipsychotics in schizophrenia. Adults (aged ?18 years) with schizophrenia who newly initiated aLAI antipsychotics (aripiprazole laurox- il, aripiprazole monohydrate, paliperidone palmitate, or risperidone) were evaluated for up to 12 months at the cli- nicians
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Simulating different switch rates of once- monthly (PP1M) and once-every-3-months (PP3M) paliperidone palmitate to once-every-6-months paliperidone palmitate (PP6M) for the management of schizophrenia in Medicare: A budget impact model (BIM) () - Apr 9, 2024 - Abstract #AMCP2024AMCP_91;
Increased switch rates from PP1M and PP3M to PP6M in Medicare for adults with schizophrenia are pro- jected to have minimal budget impact. Population health decision-makers who assess different treatment options for patients with schizophrenia can benefit more with this long-acting injectable antipsychotic with the longest dosing interval and may improve treatment adherence in patients with schizophrenia.
- | paroxetine / Generic mfg.
Journal: An Innovative SbIII-WVI-Cotemplated Antimonotungstate with Potential in Sensing Paroxetine Electrochemically. (Pubmed Central) - Apr 9, 2024
Using a 1@rGO-modified glassy carbon electrode as the working electrode, an electrochemical biosensor for detecting the antidepressant drug paroxetine (PRX) was successfully constructed. This work can provide a viable strategy for synthesizing mixed-heteroatom-directing POMs and demonstrates the application of POM-based materials for the electrochemical detection of drug molecules.
- || Fintepla (low-dose fenfluramine) / UCB, Nippon Shinyaku
Clinical, Review: Optimal dose of fenfluramine in adjuvant treatment of drug-resistant epilepsy: evidence from randomized controlled trials. (Pubmed Central) - Apr 9, 2024
The higher range of the licensed dose achieves the optimal balance between efficacy, safety, and tolerability in patients with DS and LGS. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023392454.
- | duloxetine / Generic mfg.
Journal: Duloxetine enhances the sensitivity of non-small cell lung cancer cells to EGFR inhibitors by REDD1-induced mTORC1/S6K1 suppression. (Pubmed Central) - Apr 9, 2024
Taken together, our findings reveal that the ATF4/REDD1/mTORC1/S6K1 signaling axis, as a novel mechanism, is responsible for the synergistic therapeutic effect of duloxetine with EGFR-TKIs. These results suggest that combining EGFR-TKIs with duloxetine appears to be a promising way to improve EGFR-TKI efficacy against NSCLC.